Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.62 |
| ▸ | FABP4 | P15090 | 1/20 | 0.62 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.62 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | CHAT | P28329 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CD40 | P25942 | 2/20 | 0.40 |
| ▸ | CD40LG | P29965 | 2/20 | 0.40 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13018041 | 0.85 | TTR (0.46) | TTRFABP4CCNA2CDK2MAPK14 | |
| SCHEMBL401444 | 0.84 | HSD17B10 (0.55) | TTRFABP4CCNA2CDK2MAPK14 | |
| SCHEMBL29377096 | 0.84 | HSD17B10 (0.55) | TTRFABP4CCNA2CDK2MAPK14 | |
| SCHEMBL28535503 | 0.83 | HSD17B10 (0.53) | TTRFABP4CCNA2CDK2MAPK14 | |
| SCHEMBL28533341 | 0.83 | HSD17B10 (0.53) | TTRFABP4CCNA2CDK2MAPK14 | |
| SCHEMBL21725437 | 0.81 | TTR (0.60) | TTRFABP4CCNA2CDK2MAPK14 | |
| SCHEMBL27459951 | 0.80 | TTR (0.59) | TTRFABP4CCNA2CDK2MAPK14 | |
| SCHEMBL12380350 | 0.78 | TTR (0.40) | TTRFABP4CCNA2CDK2MAPK14 | |
| SCHEMBL8514648 | 0.78 | TTR (0.56) | TTRFABP4CCNA2CDK2MAPK14 | |
| SCHEMBL30950399 | 0.78 | TTR (0.56) | TTRFABP4CCNA2CDK2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-RE44778-E1 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8633303-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120004190-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004190-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | TTR 3494/4885FABP4 1233/4885CCNA2 3014/4885 |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | TTR 3494/4885FABP4 1233/4885CCNA2 3014/4885 |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | TTR 3494/4885FABP4 1233/4885CCNA2 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.